CD274 and non-small cell lung carcinoma: The results of KEYNOTE-042 and CheckMate 227 showed that (14), compared with chemotherapy, the ICI group improved the overall survival time (OS) [Nivolumab plus ipilimumab: risk ratio (HR) 0.82, 95% CI 0.69-0.97; Pembrolizumab: (HR) 0.81, 95% ci 0.71-0.93]; In CheckMate 012 study (1), nivolumab combined with CTLA-4i ipilimumab was used to treat advanced NSCLC, and the effective rate of patients with PD-L1 ≥ 50% was over 90%.